Virological characterization of SARS-CoV-2 BA.2.86 variants by assessing antiviral susceptibility, in vivo infectivity and replicative fitness.

Virological characterization of SARS-CoV-2 BA.2.86 variants by assessing antiviral susceptibility, in vivo infectivity and replicative fitness.

Publication date: Dec 12, 2025

Open Access PDF

Concepts Keywords
Antiviral Antivirals
Fitness Omicron
Virological Replicative fitness
Vivo SARS-CoV-2

Semantics

Type Source Name
disease MESH strain
disease MESH COVID 19
drug DRUGBANK Angiotensin II
disease MESH included
disease MESH reinfections
drug DRUGBANK L-Citrulline
drug DRUGBANK Diethylstilbestrol
disease MESH des
drug DRUGBANK Coenzyme M
disease MESH NTD
disease MESH infection
pathway KEGG Viral replication

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *